Open Access Repository

Western Australia Atropine for the Treatment of Myopia (WA-ATOM) study: Rationale, methodology and participant baseline characteristics

Lee, SSY, Mackey, DA, Lingham, G, Crewe, JM, Richards, MD, Chen, FK, Charng, J, Ng, F, Flitcroft, I, Loughman, JJ, Azuara-Blanco, A, Logan, NS, Hammond, CJ, Chia, A, Truong, TT and Clark, A 2020 , 'Western Australia Atropine for the Treatment of Myopia (WA-ATOM) study: Rationale, methodology and participant baseline characteristics' , Clinical and Experimental Ophthalmology, vol. 48 , pp. 569-579 , doi: 10.1111/ceo.13736.

Full text not available from this repository.

Abstract

Importance: Atropine eyedrops are a promising treatment for slowing myopia progression in East Asian children. However, its effects on children in Australia, including those of non-Asian background, have not been well-studied.Background: The Western Australia Atropine for the Treatment of Myopia (WA-ATOM) study aims to determine the efficacy and long-term effects of low-dose atropine eyedrops in myopia control. This paper describes the study rationale, methodology and participant baseline characteristics.Design: Single-centre, double-masked, randomized controlled trial.Participants: Children (6-16 years) with spherical equivalent ≤-1.50 D in each eye, astigmatism ≤1.50 D and myopia progression by ≥0.50 D/year.Methods: Enrolled children were randomly assigned 2:1 to receive 0.01% atropine or placebo eyedrops. Participants are examined every 6 months during first 3 years of the study (2-year treatment phase followed by a 1-year washout phase), and then at a 5-year follow-up (2 years after the end of the washout phase).Main outcome measures: Annual progression rate of myopia and axial length, tolerability to eyedrops and incidence and severity of unwanted effects.Results: Out of 311 children who were referred, 242 were suitable for study participation, and 153 were subsequently enrolled. The baseline characteristics of enrolled participants are presented.Conclusions and relevance: Outcomes of the WA-ATOM study will inform on the efficacy, tolerability, safety and long-term effects of low-dose atropine eyedrops in myopia control in Australian children. The impact of ocular sun exposure, iris colour and parental myopia on the efficacy of low-dose atropine will also be assessed.

Item Type: Article
Authors/Creators:Lee, SSY and Mackey, DA and Lingham, G and Crewe, JM and Richards, MD and Chen, FK and Charng, J and Ng, F and Flitcroft, I and Loughman, JJ and Azuara-Blanco, A and Logan, NS and Hammond, CJ and Chia, A and Truong, TT and Clark, A
Keywords: atropine eyedrop, myopia, myopia control, myopia treatment
Journal or Publication Title: Clinical and Experimental Ophthalmology
Publisher: Wiley-Blackwell Publishing Asia
ISSN: 1442-6404
DOI / ID Number: 10.1111/ceo.13736
Copyright Information:

© 2020 Royal Australian and New Zealand College of Ophthalmologists

Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP